Literature DB >> 3155503

Low capacity of erythrocytes to bind with immune complexes via C3b receptor in patients with systemic lupus erythematosus: correlation with pathological proteinuria.

Y Nojima, C Terai, S Minota, K Takano, Y Miyakawa, F Takaku.   

Abstract

Erythrocytes from 51 patients with systemic lupus erythematosus and 75 controls were tested for the capacity to bind aggregated human gamma-globulin labeled with radioiodine in the presence of complement. Both in patients and controls, a trimodal distribution of binding capacity was observed. Low (less than 9% of the added radioactivity), intermediate (9-17%), and high binding (more than 17%) were observed in 13, 58, and 29% in controls and in 49, 43 and 8% in lupus patients. The low binding capacity of erythrocytes persisted even after patients entered remission following steroid therapy. A genetic control of binding capacity was supported by familial surveys. Prevalence of pathological proteinuria was significantly higher in patients with low binding capacity than those with intermediate or high binding capacity (16/25 vs 7/26, P less than 0.01). These results indicate that an impaired physiological disposal of immune complexes via the erythrocyte C3b receptor in lupus patients may contribute to the development of renal involvement.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3155503     DOI: 10.1016/0090-1229(85)90013-3

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  3 in total

Review 1.  Systemic lupus erythematosus.

Authors:  M S Klein-Gitelman; M L Miller
Journal:  Indian J Pediatr       Date:  1996 Jul-Aug       Impact factor: 1.967

Review 2.  Complement activation and complement receptors in systemic lupus erythematosus.

Authors:  J P Atkinson
Journal:  Springer Semin Immunopathol       Date:  1986

3.  The polymorphism of the C3b/C4b receptor in the normal population and in patients with systemic lupus erythematosus.

Authors:  S Van Dyne; V M Holers; D M Lublin; J P Atkinson
Journal:  Clin Exp Immunol       Date:  1987-06       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.